Skip to search formSkip to main contentSkip to account menu

DAT regimen

Known as: Daunorubicin-AraC-Thioguanine Regimen, Daunorubicin-Cytarabine-Thioguanine Regimen, MRC AML10 Study-DAT Regimen 
A regimen consisting of daunorubicin, cytarabine (Ara-C) and thioguanine, used as an induction treatment for childhood acute myeloid leukemia (AML).
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Over-stimulation of dopamine signaling is thought to underlie the pathophysiology of a list of mental disorders, such as… 
2017
2017
SUMMARY In this study, we assessed the sensitivity, specificity, and diagnostic accuracy of a previously developed direct… 
2016
2016
The prevalence of type 2 diabetes mellitus (T2DM), which leads to diabetic complications, has been increasing worldwide. The… 
Highly Cited
2011
Highly Cited
2011
Reduced functioning of the dopamine transporter (DAT) has been linked to bipolar disorder (BD). Mice with reduced DAT functioning… 
2006
2006
The expression of the dopamine plasma membrane transporter (DAT) was investigated in rat thymus and spleen by immunochemical and… 
Highly Cited
1986
Highly Cited
1986
One patient with acute nonlymphocytic leukemia (ANLL) in remission was given intensive chemotherapy (DAT regimen) as late…